Farzana Nazimuddin

TL;DR: The first models that can accurately predict which patients are likely to develop severe CRS before they become critically ill are developed, which improves understanding of CRS biology and may guide future cytokine-directed therapy.

TL;DR: Genetically engineered T cells that induced remission in a patient with chronic lymphocytic leukaemia were found to have disruption of the TET2 gene, which caused T cell changes that potentiated their anti-tumour effects.

TL;DR: It is found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration, indicating that targeting CD19 and CD123 on leukemic blasts represents an effective strategy for treating and preventing antigen-loss relapses occurring after CD19

TL;DR: A patient relapsing 9 months after CD19-targeted CAR T cell infusion with CD19– leukemia that aberrantly expressed the anti-CD19 CAR was reported.

TL;DR: Evidence is provided for the potential antitumor activity of messenger RNA CARTmeso cells, as well as PDAC resistance to the immune response, in 6 patients with chemotherapy-refractory metastatic PDAC.